Description
Key facts
Cell type:HCT116,
Species or organism:Human,
Tissue:Colon,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon1.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-NHERF1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EBP50 also known as NHERF-1 (Na+/H+ exchanger regulatory factor 1) is a scaffolding protein with a mass of approximately 50 kDa. This protein plays a critical role in the formation of multiprotein complexes by its ability to bind to several different proteins simultaneously. EBP50 localizes primarily to the apical surface of epithelial cells where it is found in organs such as the kidney liver and intestines. It consists of two PDZ domains and an ezrin-binding domain which enable it to interact with various membrane proteins cytoskeletal elements and signaling molecules.
Biological function summary
EBP50 regulates cellular functions by organizing signaling complexes at the plasma membrane. It is involved in processes such as ion transport signal transduction and cell proliferation. EBP50 often acts as part of a multiprotein complex contributing to the stabilization and regulation of membrane receptors and channels. By regulating these components EBP50 affects a variety of cellular responses to external stimuli.
Pathways
EBP50 plays important roles in cellular signaling pathways like the PTH (parathyroid hormone) receptor signaling and CFTR (cystic fibrosis transmembrane conductance regulator) channel regulation. It interacts with proteins such as ezrin and PLCβ (phospholipase C beta) which facilitates the signaling cascades critical for maintaining proper cell function. By modulating these pathways EBP50 has a significant impact on maintaining cellular homeostasis and responding to changing physiological conditions.
EBP50 has been linked to conditions such as cystic fibrosis and certain cancers. With cystic fibrosis its interaction with CFTR is essential for the proper regulation of chloride channels and subsequently fluid balance in epithelial tissues. In cancer altered expression or mutations in EBP50 can affect pathways related to cell growth and metastasis highlighting interactions with the ezrin protein which couples signals from the cell membrane to actin cytoskeleton dynamics impacting tumor progression.
